EUCTR2019-002023-15-NL进行中（未招募）1 期
Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein(rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients =12 Years of Age With Severe Hemophilia A - XTEND-1
Bioverativ Therapeutics Inc. (a Sanofi company)0 个研究点目标入组 164 人开始时间: 2019年11月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 164
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Participant, male or female, must be equal to or greater than 12 years of age inclusive, at the time of signing the informed consent.
- •2. Severe hemophilia A, defined as <1 IU/dL (<1%) endogenous FVIII activity as documented either by central laboratory testing at Screening or in historical medical records from a clinical laboratory demonstrating <1% FVIII coagulant activity (FVIII:C) or a documented genotype known to produce severe hemophilia A
- •3. Previous treatment for hemophilia A (prophylaxis or on demand) with any recombinant and/or plasma-derived FVIII, or cryoprecipitate for at least 150 EDs.
- •4. Current regimen includes one of the following:
- •Prophylactic treatment regimen with a marketed FVIII product or prophylactic emicizumab therapy for at least 6 months during the previous 12 months. Appropriate washout time needs to be taken into account.
- •On-demand regimen with a marketed FVIII product with a history of at least 12 bleeding episodes in the previous 12 months or at least 6 bleeding episodes in the previous 6 months prior to study enrollment. On-demand participant is accepting to move to a prophylaxis treatment regimen after 26-week on-demand period.
- •5. Willingness and ability of the participant or surrogate (a caregiver or a family member =18 years of age) to complete training in the use of the study electronic Patient Diary (ePD) and to use the ePD throughout the study.
- •6. Ability of the participant or his or her legally authorized representative (eg., parent or legal guardian) to understand the purpose and risks of the study, willing and able to comply with study requirements and provide signed and dated informed consent or assent (as applicable) and authorization to use protected health information in accordance with national and local participant privacy regulations.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 10
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 149
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •- Clinically significant liver disease.
- •- Serious active bacterial or viral infection (other than chronic hepatitis or HIV) present within 30 days of Screening.
- •- Other known coagulation disorder(s) in addition to hemophilia A.
- •- History of hypersensitivity or anaphylaxis associated with any FVIII product
- •- Positive inhibitor results, defined as =0.6 BU/mL at Screening. History of a positive inhibitor test defined as =0.6 BU/mL. Family history of inhibitors will not exclude the participant.
- •- Use of Emicizumab within the 20 weeks prior to Screening
- •- Major surgery within 8 weeks prior to Screening.
研究者
相似试验
进行中（未招募）
1 期
A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, BIVV001, in Patients With Severe Hemophilia A (XTEND-1)EUCTR2019-002023-15-ESBioverativ Therapeutics Inc.164
进行中（未招募）
1 期
A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, BIVV001, in Patients With Severe Hemophilia A (XTEND-1)EUCTR2019-002023-15-HUBioverativ Therapeutics Inc.164
进行中（未招募）
1 期
Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein(rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients =12 Years of Age With Severe Hemophilia A - XTEND-1severe hemophilia AMedDRA version: 20.0Level: PTClassification code 10016080Term: Factor VIII deficiencySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002023-15-BEBioverativ Therapeutics Inc. (a Sanofi company)164
进行中（未招募）
1 期
A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, BIVV001, in Patients With Severe Hemophilia A (XTEND-1)severe hemophilia AMedDRA version: 20.0Level: PTClassification code 10016080Term: Factor VIII deficiencySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002023-15-FRBioverativ Therapeutics Inc.159
进行中（未招募）
1 期
A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, BIVV001, in Patients With Severe Hemophilia A (XTEND-1)severe hemophilia AMedDRA version: 20.0Level: PTClassification code 10016080Term: Factor VIII deficiencySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002023-15-BGBioverativ Therapeutics Inc. (a Sanofi company)164